Search results
15 lis 2011 · Potential Risk Factors for VTE in Patients With Active Cancer. Patient-Related Factors. Cancer-Related Factors. Treatment-Related Factors. Demographics: age, sex, race. Primary site of cancer. Chemotherapy, hormonal, and biological therapy.
5 lis 2020 · Introduction: The risk of venous thromboembolism (VTE) is increased in cancer patients, compared to subjects without cancer. The Khorana score (KS) is used to stratify VTE risk in cancer outpatients and recent society guidelines recommend thromboprophylaxis for patients with KS≥2.
26 lis 2020 · Our findings suggest that ML tools hold promise for cardiac risk assessment for patients before, during, or after cancer treatments by integrating large‐scale, longitudinal patient data from healthcare systems.
10 sty 2023 · VTE risk assessment should be based on validated RAMs such as the KRS, the Prospective Comparison of Methods for thromboembolic risk assessment with clinical Perceptions and AwareneSS in real-life patients-Cancer-Associated Thrombosis (COMPASS-CAT) or the Vienna Cancer and Thrombosis Study (Vienna-CATS) nomogram score [III, C].
1 mar 2022 · The risk of VTE in patients with cancer profoundly depends on patient-related, tumor-related, and treatment-related risk factors as well as laboratory parameters and biomarkers [5 ]. In this narrative review, we provide an overview of the burden of cancer-associated VTE, risk factors, and risk assessment approaches.
6 dni temu · Introduction Several risk scores have been proposed to predict venous thromboembolism (VTE) in hospitalized patients. However, their predictive performances in lung cancer patients receiving immune checkpoint inhibitors (ICIs) is unclear. We aimed to validate and compare their performances of the Caprini, Padua and Khorana risk scores in lung cancer patients receiving ICIs. Methods This was a ...
1 lut 2019 · To build skills related to cancer risk assessment including: identification of elevated personal or hereditary cancer risks, incorporation of cancer risk models into clinical care, and reviewing elements of cancer risk education and informed consent.
